Monoamineoxidase-B (MAO-B) Inhibitors in theTreatment of Alzheimer's and Parkinson's Disease.
CONCLUSION: Many studies demonstrate that MAO-B activity increases with age in brain tissue, cerebrospinal fluid (CSF), and platelets in Alzheimer's patients. This suggests that MAO-B inhibitor drugs, which may be effective in the treatment of Parkinson's disease, may also be effective in the treatment of Alzheimer's disease. This article was written to explain the multifaceted MAO-B inhibitor molecules.
PMID: 33538661 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Özdemir Z, Alagöz MA, Bahçecioğlu ÖF, Gök S Tags: Curr Med Chem Source Type: research
More News: Alzheimer's | Brain | Chemistry | Depression | Jobs | Neurology | Parkinson's Disease | Study